Tarec Christoffer El-Galaly

Medicine and Dentistry

1. Age 6%
2. Analysis 11%
3. Assessment 6%
4. B Cell 5%
5. Central Nervous System 8%
6. Cohort Analysis 18%
7. Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine 6%
8. Diagnosis 13%
9. Diffuse Large B-Cell Lymphoma 50%
10. Diseases 13%
11. Fluorodeoxyglucose F 18 6%
12. Follicular Lymphoma 8%
13. Follow up 13%
14. Gene 9%
15. Hazard Ratio 7%
16. Hematological Cancer 9%
17. Hodgkin's Lymphoma 15%
18. Inpatient 22%
19. International Prognostic Index 9%
20. Lymphoma 40%
21. Malignant Neoplasm 5%
22. Neoplasm 11%
23. Non-Hodgkin Lymphoma 11%
24. Overall Survival 10%
25. Patient 100%
26. Peripheral T-Cell Lymphoma 5%
27. Personalized Medicine 9%
28. PET-CT 20%
29. Positron Emission Tomography 5%
30. Prognosis 7%
31. Prophylaxis 5%
32. Spontaneous Remission 11%
33. Therapeutic Procedure 51%